Business Wire

PHENOM

22.5.2023 11:01:29 CEST | Business Wire | Press release

Share
Phenom Named Strategic Leader in Fosway’s 9-Grid™ for Talent Acquisition 2023 for Third Consecutive Year

Phenom has been named a Strategic Leader in the 2023 Fosway 9-GridTM for Talent Acquisition for the third consecutive year, proving its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005161/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Strategic Leader position reaffirms Phenom and its Intelligent Talent Experience platform’s consistent ability to serve EMEA’s largest companies’ complex talent demands. (Graphic: Business Wire)

Job vacancy rates recently reached record highs and the competitive talent market remains a priority on the European Union’s policy agenda, according to a European Labour Authority report. To better connect with candidates and quickly fill open roles in a scalable, sustainable way, CHROs and CEOs from today’s leading enterprises are choosing holistic solutions that leverage intelligence, automation and experience to reduce repetitive tasks, increase recruiter efficiency and hyper-personalize every part of the talent journey.

“Artificial intelligence (AI) is accelerating disruption in the TA market,” said David Wilson, CEO, Fosway Group. “Phenom’s position as a Strategic Leader on the 2023 Fosway 9-Grid™ for Talent Acquisition reflects the company’s continued innovation in AI and the candidate and talent experience. Recent acquisitions continue to give the company even greater traction in the European market.”

More than 500 global, diverse enterprises use Phenom’s vast network of data, contextual industry models and deep learning to achieve measurable, defensible results. Case studies of customers using the Intelligent Talent Experience platform document their ability to:

  • Generate 11X more internal and external applications and achieved a 50% reduction in time to apply
  • Drive a 176% increase in applications and 165% increase in hires YOY
  • Deliver 8X more candidates and 20% faster hires
  • Save up to 78% of recruiters’ time with automated screening and scheduling
  • Decrease time to schedule an interview 98% (from 5 minutes to 5 seconds) with automation
  • Increase recruiter productivity 567% and reduce agency spend
  • Cut 65 days off time to hire

“Phenom continues to deliver innovation, scale technology and elevate customer support to solve the most complex talent demands of the largest enterprises across Europe,” said Mahe Bayireddi, CEO and co-founder of Phenom. “We are fully invested in the success of our customers’ teams, their outcomes and the incredible impact they’re able to drive for talent acquisition and management — and the business as a whole.”

In addition to their existing talent acquisition technology — including Career Site, CMS, CRM, Video Assessments and AI Scheduling — Phenom recently announced Phenom X+, a new platform-wide generative AI capability that bolsters efficiencies by automating content creation, surfacing actionable intelligence, and eliminating time-consuming tasks. Phenom also unveiled 18 platform intelligence and automation innovations to further transform the way employers teams hire, develop and retain talent.

Platform innovation highlights include:

  • Generative AI for TA — providing sourcers, recruiters, talent marketers, and other talent acquisition professionals the ability to generate personalized content that delights candidates and dramatically speeds up the hiring process by eliminating time-consuming, manual work.
  • High-Volume Hiring — automating job discovery, application submission, and offering extension processes for frontline and hourly workers.
  • Automation Engine — giving organizations the backend interface and control needed to configure and iterate on hiring workflows – complete with intelligence for ongoing monitoring and qualitative analysis of performance, plus recommendations to optimize in real-time.
  • Interview Intelligence — eliminating the black box of the interview process by providing transcripts, key takeaways, and actionable guidance to the hiring team to move forward with decisions faster.
  • Workforce Intelligence — providing context and oversight to HR teams within their organization, including hiring trends, churn rate, retention risks and high performers, to improve talent onboarding, development and retention.
  • Candidate Hub – bringing transparency to candidates throughout the hiring process, making it easy to discover relevant roles, understand hiring status, prepare for interviews, and reschedule when conflicts arise.

Companies across EMEA are successfully adopting Phenom’s Intelligent Talent Experience platform to help candidates find and choose them faster, employees develop their skills and evolve, recruiters become wildly productive, managers build stronger-performing teams, HR align employee development with company goals and HRIS create a holistic tech infrastructure through seamless integrations.

To learn more about Phenom’s Strategic Leader position, read this blog.

To see the Phenom Intelligent Talent Experience platform in action, request a demo.

About the Fosway 9-Grid™

Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organizations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organizations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.

About Phenom

Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.

Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005161/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye